Oral anticoagulation in patients with left ventricular thrombus: a systematic review and network meta-analysis with reconstructed time-to-event data.
Sebastian HeyneSascha Macherey-MeyerMax M MeertensKarl FinkeStephan BaldusChristoph AdlerSamuel LeePublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2024)
In this NMA, Rivaroxaban showed faster LVT resolution and consecutively lower odds of ischemic stroke than VKAs while Apixaban and Dabigatran showed at least equal efficacy. Given the quality and size of the available studies, these differences between individual DOACs should be acknowledged as hypothesis generating only. Future adequately powered randomized controlled trials are needed to assess possible time-varying effects between individual DOACs.
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- left atrial
- venous thromboembolism
- left ventricular
- heart failure
- randomized controlled trial
- catheter ablation
- percutaneous coronary intervention
- electronic health record
- current status
- acute myocardial infarction
- single molecule
- big data
- mitral valve
- aortic stenosis
- quality improvement
- machine learning
- pulmonary embolism
- acute coronary syndrome
- deep learning